Skip to main content

Table 3 Result of the comparison of BCVA and CFT before and 12 months after the implementation of DEX treatment

From: Pseudophakic macular edema in nondiabetic and diabetic patients without diabetic retinopathy treated with intravitreal dexamethasone implant

 

0 M

1 M

3 M

6 M

12 M

p*

Total (n = 42)

 BCVA (LogMAR)

0.80 ± 0.31

0.65 ± 0.35

0.56 ± 0.31

0.41 ± 0.22

0.35 ± 0.17

< 0.001

 BCVAΔ (change)

–

− 0.15 ± 0.26

− 0.24 ± 0.26

− 0.40 ± 0.27

− 0.45 ± 0.24

 CFT (µm)

555.07 ± 149.63

361.79 ± 119.43

397.57 ± 169.18

337.48 ± 106.06

314.21 ± 77.06

< 0.001

 CFTΔ (change)

–

− 193.29 ± 104.55

− 157.50 ± 126.21

− 217.60 ± 120.52

− 228.26 ± 156.79

Nondiabetic (n = 21)

 BCVA (LogMAR)

0.63 ± 0.25

0.54 ± 0.42

0.42 ± 0.31

0.31 ± 0.25

0.28 ± 0.17

< 0.001

 BCVAΔ (change)

–

− 0.09 ± 0.23

− 0.21 ± 0.26

− 0.32 ± 0.25

− 0.35 ± 0.17

 CFT (µm)

494.43 ± 99.73

318.67 ± 44.49

349.33 ± 94.13

329.43 ± 97.62

298.71 ± 42.05

< 0.001

 CFTΔ (change)

–

− 175.76 ± 63.41

− 145.10 ± 125.53

− 165.00 ± 114.79

− 195.71 ± 93.23

Diabetic w/o DR (n = 21)

 BCVA (LogMAR)

0.98 ± 0.28

0.75 ± 0.21

0.70 ± 0.24

0.50 ± 0.14

0.42 ± 0.13

< 0.001

 BCVAΔ (change)

–

− 0.22 ± 0.27

− 0.27 ± 0.26

− 0.47 ± 0.28

− 0.55 ± 0.26

 CFT (µm)

615.71 ± 168.01

404.90 ± 152.84

445.81 ± 211.97

345.52 ± 115.73

329.71 ± 99.51

< 0.001

 CFTΔ (change)

–

− 210.81 ± 133.20

− 169.90 ± 128.74

− 270.19 ± 103.88

− 260.81 ± 198.69

  1. 0 M 60 days after topical treatment and DEX implant occurrence, 1 M 1 month after DEX implant, 3 M 3 months after DEX implant, 6 M 6 months after DEX implant, 12 M 12 months after DEX implant, BCVA corrected distance visual acuity, CFT central foveal thickness, µm micrometer, w/o without, DR diabetic retinopathy
  2. *Test of Friedman’s ANOVA
Back to article page

International Journal of Retina and Vitreous

ISSN: 2056-9920

Contact us